This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Chronic obstructive pulmonary disease, known commonly as COPD, is a condition that impacts more than 16 million Americans. COPD is a chronic, inflammatory lung disease that obstructs the airflow to and from the lungs, and common symptoms include a continual cough, shortness of breath, excess mucus, and chest tightness.For those living with COPD, their loved ones, and their care partners, we’re sharing some helpful resources to gain information and build community.
This chart shows the drugs with the most patents in France. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in France? appeared first on DrugPatentWatch - Make Better Decisions.
Today’s guest post comes from ConnectiveRx’s Lauren Cole, Senior VP of Launch Excellence at ConnectiveRx. Lauren outlines key success factors when transitioning or launching a patient hub. To learn more, join Lauren on April 4th at 1:00 p.m. ET for a free online panel discussion: Lessons from the Edge—Six Things That Can Make a Hub Launch Go Wrong. Lauren will also be exploring hub launch excellence at Informa Connect’s Hub and Specialty Pharmacy Models East conference on March 20-22.
Many workers who were on the frontlines during the COVID-19 pandemic experienced increased physical and mental stress. One study found that 70% of U.S. workers felt more stressed at work during COVID-19 than at any other point in their professional careers [1]. Public health workers, including epidemiologists, contact tracers, laboratory scientists, community health workers, and data analysts, served on the front lines of the pandemic delivering information, providing services, and conducting re
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Those familiar with simulation-guided design (SGD) know that it can be used for a wealth of clinical trial options: endpoint selection, number and timing of interim analyses, hitting recruitment targets, managing risk, and building in trial efficiencies. Recently, decision-makers have commented on SGD’s ability to “super-charge” quantitative decision-making for “productive evidence-based conversations.
Annual Drug Patent Expirations for XHANCE Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Optinose Us drug XHANCE appeared first on DrugPatentWatch - Make Better Decisions.
As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Unfortunately, we should expect most PBMs and plan sponsors to embrace the high-list/high-rebate version.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Unfortunately, we should expect most PBMs and plan sponsors to embrace the high-list/high-rebate version.
Avian influenza (bird flu) is caused by infection with avian influenza (flu) Type A viruses. These viruses routinely spread among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Sporadic human infections with bird flu viruses have occurred. Avian influenza A viruses are classified into the following two categories: Highly pathogenic avian influenza (HPAI) virus strains are extremely infectious, often fatal to chickens, and can spread rapidly from f
DrugBank is passionate about equipping leading researchers with the data they need for new discoveries. As a trusted partner to world-renowned researchers, we are proud to be contributing to groundbreaking research and aiding in solving some of the industry's most pressing issues. Our team is excited to spotlight a handful of impressive academic researchers, their work, and how they've used DrugBank to power their research.
This chart shows the patent expirations for capsule dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Capsule dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Informa Connect’s Access USA Hybrid Event | March 20-23, 2023, Philadelphia Marriott Downtown www.informaconnect.com/accessusa Exclusive Offer – Be sure to use your exclusive promo 23AUSA10 to save 10% off* of your registration We would like to introduce to you Access USA , industry’s resource for accelerating access, partnerships and collaboration to deliver superior patient outcomes.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Lupus is a chronic autoimmune disease that causes the body to attack its own tissues and organs. For the 1.5 million people in the United States that live with the disease, it has severe implications — symptoms include pain, fatigue, hair loss, cognitive issues, physical impairments, and disfiguring rashes. An estimated 10-15% of lupus patients will die prematurely due to the condition.
The news surrounding recent mass layoffs has been hard to miss and may even have you taking a closer look at the companies you choose to do business with. When it comes to evaluating vendors for your eClinical solutions, here are a few positive attributes to look for that serve as a recipe for longevity and sustainability. The post 3 Reasons Why Business Model Matters When Selecting an eClinical Technology Partner appeared first on Crucial Data Solutions.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Estonia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Estonia? appeared first on DrugPatentWatch - Make Better Decisions.
Over the past years, probably the entire last decade, there have been several discussions on how to handle multiple subjects’ enrollments in CDISC data packages. Members of the CDISC SDS Multiple Subject Instances (MSI) team also shared some previews of future possible modifications of the SDTM standard to handle multiple subjects’ enrollment, [i] and we might finally have something available with the upcoming future releases of the SDTM standard and Implementation Guidance (IG).
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
As appeared in Precision Oncology News. NEW YORK – Predictive Oncology wants to ink more partnerships with biopharmaceutical companies and demonstrate the ability of its commercially available PEDAL platform to provide early insights that sponsors can use to prioritize drugs for development and identify biomarker-informed indications. Predictive Oncology’s Patient-centric Drug Discovery by Active Learning (PEDAL) platform uses artificial intelligence and a proprietary biobank to generate drug r
This chart shows the pharmaceutical companies with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.
Advancements in organoid technology have led to novel stem cell–based models that reflect important structural and functional properties of the tissue from which the cells were derived in vivo. These models provide more clinically relevant platforms that can help researchers better select agents to advance to the clinic.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
We’re excited to share that today, we announced a partnership with XpertPatient, an award-winning educational website that provides support to newly-diagnosed cancer patients. We are providing the XpertPatient community with access to Antidote Match™, our patient-friendly clinical trial search that currently powers clinical trial matching for 300+ patient organizations.
Precision for Medicine will be exhibiting at booth 55 at OCT West Coast. Stop by out booth or schedule a meeting here. The post OCT West Coast (March 1-2) appeared first on Precision For Medicine.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Germany. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Germany? appeared first on DrugPatentWatch - Make Better Decisions.
JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at Labcorp are dedicated to improve the cardiovascular health of patients worldwide, as part of Labcorp’s mission to improve health and improve lives. This … The post Delivering solutions to the next generation of cardiovascular medicines appeared first on Insights From Our Labs to Yours.
When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. At Worldwide, this topic arises frequently in discussion with rare disease sponsors.
Clinical trial patient recruitment is a major challenge in the industry — 85% of trials fail to recruit enough patients , 80% are delayed due to recruitment problems, and dropout rates soar. Both at the recruitment and retention stages, taking a patient-centric approach to clinical trial design is a must in order to set your trial up for success.
Annual Drug Patent Expirations for NEXAVAR Nexavar is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are three patents… The post New patent expiration for Bayer Hlthcare drug NEXAVAR appeared first on DrugPatentWatch - Make Better Decisions.
> I’ll start this post by with reference to a disease that some of you many never have heard of. Chagas disease is caused by the very nasty T. cruzi parasite (not to be confused with the even nastier American politician) and is of particular interest in Latin America where the disease is endemic. T. cruzi parasites have an essential requirement for ergosterol and, as discussed in C2010 , are potentially vulnerable to inhibition of sterol 14α-demethylase (CYP51), which catalyzes the conversion
Precision for Medicine is excited to be exhibiting and speaking at AACR in Orlando, Florida. Stop by the booth or schedule a meeting here. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Today’s guest post by Reed Smith’s Kevin Hara arises indirectly from the Zantac MDL, but addresses a recurring preliminary question of federal jurisdiction − fraudulent joinder. That issue, in turn, involves product identification (another problem in MDLs) and a pointer for pharmacies that want to avoid being involved in pharmaceutical litigation. As always our guest posters deserve 100% of the credit (and any blame) for what they have to say. * This guest writer has always viewed the phrase “Ab
Annual Drug Patent Expirations for CARDENE Cardene is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are five patents protecting… The post New patent for Chiesi drug CARDENE appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CARDENE+IN+0.86%25+SODIUM+CHLORIDE+IN+PLASTIC+CONTAINER Cardene In 0.86% Sodium Chloride In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from… The post New patent for Chiesi drug CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CARDENE+IN+0.83%25+SODIUM+CHLORIDE+IN+PLASTIC+CONTAINER Cardene In 0.83% Sodium Chloride In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from… The post New patent for Chiesi drug CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CARDENE+IN+4.8%25+DEXTROSE+IN+PLASTIC+CONTAINER Cardene In 4.8% Dextrose In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from two… The post New patent for Chiesi drug CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CARDENE+IN+5.0%25+DEXTROSE+IN+PLASTIC+CONTAINER Cardene In 5.0% Dextrose In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from two… The post New patent for Chiesi drug CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content